Trials / Completed
CompletedNCT06444191
Pharmacokinetics (PK) of Rilzabrutinib (PRN1008) in Healthy Japanese and Caucasian Subjects
A Phase 1, Single-Center, Open-Label Study to Evaluate the Pharmacokinetics and Tolerability of Rilzabrutinib (PRN1008) in Japanese and Caucasian Healthy Male and Female Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Principia Biopharma, a Sanofi Company · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
This is a single-dose and multiple doses study to assess the Pharmacokinetics (PK) of rilzabrutinib as well as to evaluate the tolerability of rilzabrutinib in Japanese and Caucasian Healthy Male and Female subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rilzabrutinib | Rilzabrutinib tablet(s) administered orally |
Timeline
- Start date
- 2021-01-04
- Primary completion
- 2021-04-12
- Completion
- 2021-04-12
- First posted
- 2024-06-05
- Last updated
- 2024-06-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06444191. Inclusion in this directory is not an endorsement.